Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell‐surface CXCR4 as a synergistic target for combinatorial therapy
BTKi are preferred in clinical practice over idelalisib due to lower toxicity, but idelalisib plus anti ‐ CD20 antibodies remains relevant in the treatment of CLL cases resistant to BTKi and vene-toclax, in BTKi ‐ intolerant patients, and next ‐ generation PI3Ki such as duvelisib or umbralisib are being developed.
Abstract
BTK and PI3K δ inhibitors (BTKi/PI3Ki) targeting kinases associated with the B ‐ cell receptor (BCR) pathway are highly effective in chronic lymphocytic leukemia (CLL), and BTKi represent a cornerstone of CLL therapy. BTKi are preferred in clinical practice over idelalisib due to lower toxicity, but idelalisib plus anti ‐ CD20 antibodies remains relevant in the treatment of CLL cases resistant to BTKi and vene-toclax, in BTKi ‐ intolerant patients, and next ‐ generation PI3Ki such as duvelisib or umbralisib are being developed. Notably, BTK and PI3K are involved in distinct parts of the BCR cascade, yet their inhibition produces similar effects, including disruption of CLL cell migration and adhesion, leading to peripheral blood lymphocytosis. 1,2 To increase clinical efficacy, BTKi/PI3Ki are commonly used in combination with anti ‐ CD20 antibodies and/or with the BH3 mimetic venetoclax. However, CD20 expression is significantly repressed by BTKi or PI3Ki therapy, 3,4 which
The receptor tyrosine kinase‑like orphan receptor (ROR1) is aberrantly expressed on chronic lymphocytic leukemia (CLL) cells and promotes survival signaling through NF‑κB, ERK1/2, and mTORC1. Zilovertamab is a humanized monoclonal antibody targeting ROR1. We conducted a multicenter phase 1b/2 study of zilovertamab plus...
M. Choi, E. Ghia, T. Siddiqi et al.· Leukemia· 0 citations
Background/Objectives: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) improves outcomes in relapsed/refractory large B-cell lymphoma (LBCL), but many patients relapse despite retained CD19 expression. We explored baseline tumor transcriptional features associated with ev...
Jean Silva de Souza Resende, I. S. Giner, Maria Gabriela Custodio de Figueiredo et al.· Medical Science· 0 citations
Natural killer/T‐cell lymphoma (NKTCL) is an aggressive lymphoma subtype with limited treatment options, especially for relapsed or refractory patients. Chidamide, a histone deacetylase inhibitor, and linperlisib, a phosphatidylinositol‐3‐kinase (PI3K) inhibitor, have shown promise in treating peripheral T‐cell lymphom...
Wen-Xing Jiang, Zhuang-Zhuang Shi, Zhao-Ming Li et al.· Hematological Oncology· 0 citations
AIM: Activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) has poor response to standard rituximab combined chemotherapy regimen and poor clinical prognosis. The aim of this study is to investigate the in vitro experimental basis for the clinical application of the three-drug combination (Zanubrutinib, Lenali...
Ting Wei, Xiaoting Liao, Yue Wang et al.· International Journal of Bio...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in the United States and is associated with dismal prognosis. Recent studies revealed that LY6D expression is elevated in PDAC and correlates with poor patient survival. However, the functional role of LY6D in PDAC progressio...
Yong-chul Kim, Deepak Rohilla, David J. Wisniewski et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.